Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Pipeline Review, H1 2017

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0782TDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Pipeline Review, H1 2017

Summary

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The latest report Histone Deacetylase 8-Pipeline Review, H1 2017, outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 5, 1 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adenoid Cystic Carcinoma (ACC), B-Cell Non-Hodgkin Lymphoma, Bone Disorders, Brain Cancer, Cognitive Disorders, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Renal Cell Carcinoma and T-Cell Leukemia.

Furthermore, this report also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)

The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Overview

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Companies Involved in Therapeutics Development

Chipscreen Biosciences Ltd

HitGen LTD

NatureWise Biotech & Medicals Corp

Sigma-Tau SpA

Zhejiang Hisun Pharmaceutical Co Ltd

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Drug Profiles

HG-3001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

largazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-140-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HDAC 8 for Pancreatic Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HDAC for Prostate Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tucidinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Dormant Products

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)-Product Development Milestones

Featured News & Press Releases

Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer

Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan

Sep 03, 2015: HUYA Bioscience International Announces Epigenetic Breast Cancer Program

Aug 27, 2015: HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting

Mar 19, 2015: HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan

Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China

Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China

Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation

Nov 06, 2013: The CSO of Chipscreen Biosciences was invited to speak at "The 4th CPA-RSC Symposium on Medicinal Chemistry: Epigenetics as Targets for Drug Discovery"

Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China

Jul 24, 2012: Chidamide is scheduling to file NDA by the end of this year

Aug 23, 2010: Chidamide (CS055) obtained permission from SFDA to enter into Phase II and III clinic studies for NSCLC, Breast and Prostate cancer in China

Jan 23, 2010: Chidamide (CS055) won US FDA nod to enter into clinic trials in the US

Feb 26, 2009: Chidamide (CS055) won orphan drug designation from SFDA to enter into NDA-directed clinic study for CTCL

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Chipscreen Biosciences Ltd, H1 2017

Pipeline by HitGen LTD, H1 2017

Pipeline by NatureWise Biotech & Medicals Corp, H1 2017

Pipeline by Sigma-Tau SpA, H1 2017

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017

Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Chipscreen Biosciences Ltd, HitGen LTD, NatureWise Biotech & Medicals Corp, Sigma-Tau SpA, Zhejiang Hisun Pharmaceutical Co Ltd

select a license

Single User License
USD 3500 INR 228200
Site License
USD 7000 INR 456400
Corporate User License
USD 10500 INR 684600

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com